Galectin Therapeutics to Present at the Singular Research Summer Conference
July 07 2017 - 12:00PM
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading
developer of therapeutics that target galectin proteins, today
announced that Harold Shlevin, Ph.D., the Company’s chief operating
officer, will be presenting on behalf of the Company at the
Singular Research Summer Solstice Conference being held on
Thursday, July 13, 2017 at the Metro Meeting Centers in Boston, MA.
Dr. Shlevin’s presentation is scheduled to begin at 3:30 p.m. ET.
A live webcast of the presentation may be accessed on the
Investor Relations section of the Galectin Therapeutics website at
www.galectintherapeutics.com. A replay of the webcast will be
available after the event.
In addition to his presentation, Dr. Shlevin will take part in a
series of 1x1 and small group meetings.
Singular Research is a trusted supplier of independent,
single-source research on small-to-micro cap companies to
small-to-medium sized Hedge Fund managers. Singular Research
provides quarterly updates for over 40 companies.
About Galectin TherapeuticsGalectin
Therapeutics is developing promising therapies for the treatment of
fibrotic liver disease, skin diseases, and cancer based on the
Company's unique understanding of galectin proteins, which are key
mediators of biologic function. Galectin seeks to leverage
extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024